CA2558877A1 — Solifenacin succinate-containing composition
Assigned to Astellas Pharma Inc · Expires 2005-08-18 · 21y expired
What this patent protects
A composition comprising solifenacin succinate with the content of impurities reduced, which can be used as a pharmaceutical primary material. This composition comprising solifenacin succinate is especially featured by reduction of the content of optical isomers thereof as compar…
USPTO Abstract
A composition comprising solifenacin succinate with the content of impurities reduced, which can be used as a pharmaceutical primary material. This composition comprising solifenacin succinate is especially featured by reduction of the content of optical isomers thereof as compared with the conventional compositions containing solifenacin acid adduct salts and can be used in the production of pharmaceutical products containing solifenacin succinate. There is further provided a process for easily producing this composition comprising solifenacin succinate.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.